Kairos Pharma KAPA 深 沪
已收盘 10-09 16:00:00 美东时间
0.8103
-0.149
-15.55%
华盛通- 最 高1.0039
- 今 开0.911
- 成交量 64.01万股
- 最 低 0.7827
- 昨 收 0.9595
- 总市值 274.32万
- 52周最高 8.5274
- 市盈率 静 --
- 换手率 18.91%
- 52周最低 0.7827
- 委 比 2.10%
- 总股本 338.54万
- 历史最高 28.00
- 量 比 0.19
- 振 幅 23.05%
- 历史最低 0.7827
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer
Kairos Pharma Ltd. (NYSE:KAPA) on Tuesday announced interim efficacy results from its ongoing Phase 2 clinical trial testing ENV-105 alongside apalutamide for patients with metastatic castration-resistant prostate cancer. The interim evaluation demonstrated a statistically significant improvement in...
10-07 02:13
Kairos Pharma Reports Strong Interim Results for ENV-105 Combo
The latest update is out from Kairos Pharma, Ltd. ( ($KAPA) ). On October 6, 20...
10-06 19:58
Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects PDD Holdings Inc – ADR (NASDAQ:PDD) to post quarterly earnings at $2.77 per share on revenue of $17.13 billion before the opening bell, according to...
08-24 14:30
Kairos Pharma announces 1-for-7 reverse stock split to maintain NYSE compliance
Kairos Pharma (KAPA) announced on Friday that it will conduct a 1-for-7 reverse stock split effective September 1, 2026, before the market opens. The company’s shares will continue trading on the NYS...
08-22 04:38
Kairos Pharma Announces 1-For-7 Reverse Stock Split, Effective Sept. 1
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is...
08-22 04:30
Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in...
07-22 20:37
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?
Kairos Pharma, Ltd. (NYSE:KAPA) shares surged 22.64% to $0.39 in after-hours trading on Wednesday following the company’s announcement of positive interim safety data for its lead cancer drug candidate. The stock had closed down 6.47% at $0.32 during regular trading. Safety Data Fuels Investor Optim...
07-16 14:51
Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate
Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same
04-01 06:37
Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates, Financial Terms Undisclosed
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn
02-26 20:14
